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Abstract: Systemic lupus erythematosus is a classical systemic autoimmune disease that overactivates
complement and can affect all organs. Early diagnosis and effective management are important
in this immune-complex-mediated chronic inflammatory disease, which has a strong component
of vasculitis and carries an increased risk of thrombosis, even in the absence of antiphospholipid
antibodies. Development of lupus nephritis can be life limiting but is managed with dialysis and renal
transplantation. Therefore, data have become available that cardiovascular risk poses a serious feature
of systemic lupus erythematosus that requires monitoring and prospective treatment. Cell-derived
microparticles circulate in plasma and thereby intersect the humoral and cellular component of
inflammation. They are involved in disease pathophysiology, particularly thrombosis, and represent
a known cardiovascular risk. This viewpoint argues that a focus on characteristics of circulating
microparticles measured in patients with systemic lupus erythematosus may help to classify certain
ethnic groups who are especially at additional risk of experiencing cardiovascular complications.
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1. Background
Systemic lupus erythematosus (SLE) is an immune-complex-driven disease which engages
complement activation via recognition of circulating and bound immune complexes by the classical
pathway. In patients, consumption of complement components occurs and its ability to remove
immune complexes becomes exhausted. Overactivation of complement in SLE patients is generally
noted, leading to the consumption of C3, C4, and a low haemolytic activity test, CH50. A deficiency or
low activity of the classical pathway of complement activation predisposes to SLE [1].
Microparticles are inflammatory buddings from cells (between 0.1 and 1 µm) [2], which themselves
sustain the inflammatory reaction in autoimmune disease [3]. Microparticles are released from activated,
apoptotic or dying cells by a process called blebbing whereby membrane remodelling modification
and phosphatidylserine exposure result in an extrusion incorporating parental surface proteins and
contents [4]. They are composed of the cell surface proteins and the cytoplasmic contents of their parent
cell, are biologically active, and they can act as biomolecular vehicles, transporting proteins and effector
molecules to distant sites and affecting target cell function [5]. Microparticles can be isolated from
samples (usually plasma or tissue culture supernatants) using serial centrifugation. Flow cytometry is
the gold standard method of microparticle analysis [6], whereby microparticles can be enumerated
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and antibodies to cell surface molecules used for the identification of microparticle phenotype and
parental origin.
They are found elevated at significant circulating levels in the blood of patients with SLE [7]
and can act as platforms for the assembly of immune complexes and sites of complement activation.
Microparticles contribute to the pathogenesis and severity of rheumatic disease, including SLE [8].
Microparticles fuse with target cells and release the contents of their parent cell such as miRNA [9],
reactive oxygen species and cytokines [10]. The pathogenesis of the inflammatory response and failure
to clear apoptotic cells and debris in SLE could also be further exacerbated by microparticles due to
their stimulating and immune complex properties [11].
An indifferent outcome of the extent of complement activation in relation to tissue damage was
reported in patients with SLE [12] but immunoglobulin binding subsets of microparticles, which fix
complement, are more likely to follow disease activity [13]. Their association with cardiovascular
risk in patients with SLE has not yet been studied. A need for studies that stratify severity to novel
biomarkers has recently been identified [14].
2. Gap in Knowledge
There is an increased incidence of endothelial dysfunction and signs of early atherosclerosis in
SLE [15]. Indeed, premature coronary atherosclerosis in SLE constitutes a challenge in the management
of patients, the higher risk being due to chronic inflammation and medication [16].
Microparticles are an integral part in the inflammatory reaction of cells and favour a systemic
disease. Platelet-derived microparticles generate thrombin, thereby aggravating hypercoagulability.
Circulating microparticles, including those derived from endothelial cells, are novel biomarkers
in SLE [17], but studies have not related these to clinical disease activity [3,18–20] or evaluated
for cardiovascular risk in SLE the proportion of IgG-decorated microparticles that also fixed
complement [21].
3. Endothelial-Derived Microparticles as Markers of Disease Activity in SLE
Endothelial cell-derived microparticles were significantly elevated in patients with SLE [22]. Events
positive for Annexin V (microparticle marker) and CD31 (endothelial marker) and negative for CD42b
(platelet marker) (Annexin V+/CD31+/CD42b−) were defined as endothelial-derived microparticles.
In a longitudinal study, their levels correlated inversely with endothelial dysfunction, measured
clinically as flow mediated dilatation of the brachial artery. On follow-up, when the overall clinical
score had improved, levels of endothelial cell-derived microparticles were reduced while endothelial
dysfunction had normalised [23]. At the same (lower) clinical score, a different study also showed no
elevation of endothelial derived microparticles, but evidence of increased microparticles derived from
non-lymphoid leukocytes, with markers of apoptosis and elevated glycolytic enzymes [24].
The fraction of endothelial cell-derived microparticles expressing VCAM-1 or C4d was shown to
be increased in patients with SLE and vascular disease compared to matched controls [7]. VCAM-1 is a
relevant factor because it is a marker of endothelial activation, and its circulating level is considered to
predict cardiovascular mortality in SLE [25]; C4d association with microparticles indicates progression
of complement activation downstream of C1 binding of bound immunoglobulins. Upon binding of C1,
composed of C1q C1r2 C1s2, to immunoglobulins, a conformational change, autoactivation of dimeric
C1r and subsequent activation of dimeric C1s activate the substrate C4. Continuous activation of
complement in systemic disease may lead to depletion of individual components; therefore, C4d is
used as a biomarker of immune-complex-mediated renal involvement [26].
4. Hypothesis Driven Outlook
To gauge the cardiovascular risk of patients with SLE, the carotid intima and media thickness
is measured by ultrasound. Many factors have been identified that cooperate in the development of
premature atherosclerosis in SLE [27], however, there is diagnostic room for an integrative approach
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to identify complement activating microparticles at the intersection with the activated endothelium,
as novel biomarkers of disease activity. This pursuit, in line with Felten et al.’s third goal (“deriving
more comprehensive tools for the evaluation of disease”) [28], may yield revelatory modulators of
disease activity that impacts the cardiovascular risk in SLE.
It is important to note that a reduced total copy number of C4 has previously been associated with
increased risk to develop SLE [29] and that the C4A allotype (that forms amide bonds with peptides
(unlike C4B allotype, which forms ester bonds with carbohydrate surfaces) is important in immune
complex induced activation and clearance. C4b is deposited on microparticles [30]. Complement
C4 copy number variation has not yet been studied in relation to the inflammatory capacity of
microparticles but has been identified as an important determinant in SLE for individuals of Southeast
Asian origin [31]. Indeed, complement activation has been in the focus of cardiovascular risk in South
Asians for a while [32–34].
5. A Necessary Focus on Patients with SLE Who Are of South Asian Origin
South Asian individuals have elevated levels of oxidative stress, measured as prostaglandin-F1α
oxidative metabolite levels from urine [35], have increased circulating microparticle counts compared
to white individuals [36] and are at a disproportionately higher risk of cardiovascular events [37]
compared to white individuals; however, the cellular and molecular reasons for this are unclear. South
Asian patients suffering from ischemic events showed an increase in circulating endothelial-derived
microparticles, but the study did not compare the extent of this increase in another population [38].
South Asian patients with SLE have a higher prevalence of subclinical atherosclerosis and
endothelial dysfunction [39] and a higher incidence of thrombotic events [40]. It is known that South
Asians develop more severe lupus disease [41]. We think that South Asian patients with SLE constitute
a group in whom to test whether complement-fixing IgG containing endothelial-derived microparticles
correlate with endothelial inflammation (Figure 1). This is of interest for two reasons: first, to lead on
to mechanistic evaluation of the increased risk of cardiovascular complications experienced by South
Asians with SLE; second, to stratify a heterogenous population and aid in the clinical management of
their disease, where lupus related renal failure remains a leading cause of death [42], and thrombotic
risk has not yet been assessed [43]. Incidence of SLE, particularly in Black African Minority Ethnic
(BAME) individuals, is more prevalent and possibly underdiagnosed, perhaps due to its complex
clinical and serological presentation and relapsing character [44]. These individuals are also at risk of
premature cardiovascular complications and infection, and this egregious disparity is of great concern
but understudied. Further understanding of the pathogenesis and pathophysiology of lupus disease
in ethnic individuals is required.
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Figure 1. VCAM-1 expressing endothelial eri ed microparticles that fix immunoglobulins and
activate complement circulate in SLE and are pathogenically important mediators of cardiovascular
risk, particularly in patients of South Asian origin. Our viewpoint proposes an microparticle-centric
analysis of patients to propel understanding of disease and support patient-centred treatment. iEC,
inflamed endothelial cell; This Photo (balance) by Unknown Author is licensed under CC BY-SA-NC.
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